Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia participants to accelerate biomarker discovery. Data will be openly shared and linked with clinical and genetic information to support AI-driven research and improve diagnosis and treatment development. This initiative is part of the CLARiTI alliance and aims to deepen understanding of neurodegenerative diseases through large-scale, multi-marker blood testing.
Borders & Southern Petroleum is progressing discussions with multiple parties to farm out its Darwin oil discovery in the Falkland Islands, amid growing investor interest driven by accelerated development of the Sea Lion oil project. The company owns...
Solana (SOL) has surged more than 24% in the past week and 43% over the last month, reclaiming the $100 price level. Institutional and whale investors, including DeFi Development Corp (DFDV), which added 19,000 SOL to its 2.3 million token holdings, ...
Dunkin' and BARK opened their first official dog drive-thru in Quincy, Massachusetts, on National Dog Day, offering dog treats, limited-edition bandanas, and plush toys inspired by Dunkin's menu. The event supports the Dunkin' Joy in Childhood Founda...
US-listed XRP ETFs attracted $28.14 million on August 26, marking the second-largest daily inflow in 2026, led by Bitwise with $13.12 million. Whale wallets accumulated about 460 million XRP tokens, the strongest since February, signaling strong inst...
At Bitcoin Asia 2026 in Hong Kong, former Binance CEO Changpeng Zhao predicted Bitcoin will overtake gold's significance during the next bull market cycle. While gold's market cap is about $32.4 trillion, Bitcoin currently holds $1.6 trillion, with Z...
